ISU Abxis, Celltrion Bukwang record highest R&D/sales ratio in order
While KOSPI listed pharmaceutical companies had narrowly enlarged R&D expenses in the 1st half of this year compared to the same period of the last year, KOSDAQ listed pharmaceutical companies stayed the same in the index. In the R&D expense/sales ratio, KOSDAQ listed pharmaceutical companies exc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
